Cognitive Function of Alcoholic Compensated Liver Cirrhosis

NCT ID: NCT04557774

Last Updated: 2020-09-22

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 110 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2011-10-01
• Study Completion Date: 2020-05-31

Brief Summary

Differences in cognitive function between patients with viral and alcoholic compensated liver cirrhosis

Detailed Description

Hepatic encephalopathy (HE) is one of the important complications of liver cirrhosis (LC). HE exhibits alterations in cognitive, psychomotor-intellectual, emotional, behavioral, or fine-motor functions. Approximately 22-74 % of patients with non-fulminant HE have MHE with a frequency proportional to the patient age and the severity of the liver disease. Patients with MHE exhibit disability in most functional behaviors such as social connection, alertness, emotional behavior, sleep, work, and leisure.

Alcohol consumption itself has a toxic effect on the brain. It has been documented that there is a neuronal loss in the cerebral cortex, hypothalamus, hippocampus, septal region, and cerebellum of an alcoholic brain.

The major causes of LC are hepatitis B/C viral infection and chronic alcohol consumption. The most widely accepted theory of HE pathogenesis is that toxic substances derived from the gut affect cerebral function after liver dysfunction or portosystemic shunting. This proposed pathogenetic mechanism could apply to viral compensated LC. However, it is difficult to explain the development of MHE in patients with alcoholic LC in this manner.

Therefore, patients with alcoholic LC may have different cognitive dysfunction as compared to patients with viral LC.

Conditions

Alcoholic Liver Disease

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Liver cirrhosis group

All included patients were asymptomatic at the baseline with no evidence of neurological impairment. Patients with a history of moderate alcohol drinking plus hepatitis B/C virus infection, medication for sedation, MELD (Model for End-stage Liver Disease) score of more than 20, OHE, seizure, head trauma, stroke, dementia, Parkinson's disease, or any kind of focal neurologic deficits were excluded. Any patients who were suspected of alcohol induced direct neurologic damages such as Wernicke's encephalopathy, alcohol induced spinal cord disease, or alcohol induced peripheral nerve disease were excluded. After evaluating the data including the laboratory findings, image findings, endoscopic findings, and medical records of all these patients, as well as liver biopsy findings for some patients, we sub-classified these 88 patients into two groups: alcoholic LC and viral LC. Finally, 80 patients (viral: 37; alcohol: 43) with compensated LC were prospectively considered in this study.

Cognitive function test

Intervention Type: OTHER

Laboratory and imaging test

• Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol.
• Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers

Neuropsychological test

-Attention, Language, Visuospatial, Memory, Frontal/executive

Interventions

Cognitive function test

Laboratory and imaging test

• Biochemical serum test: total bilirubin, alanine aminotransferase (ALT), haptoglobin, aspartate aminotransferase (AST), gamma glutamyltranspeptidase (GGT), alkaline phosphatase (ALP), albumin, blood urea nitrogen, creatinine, α-fetoprotein (AFP), prothrombin time, blood glucose, triglycerides, and total cholesterol.
• Baseline evaluations: family and alcohol history, X-ray, electrocardiography, blood tests for electrolyte, liver function, and viral markers

Neuropsychological test

-Attention, Language, Visuospatial, Memory, Frontal/executive

Intervention Type: OTHER

Other Intervention Names

Laboratory, imaging, neuropsychological tests

Eligibility Criteria

Inclusion Criteria

• Those who agreed to participate in this study and signed a written consent
• Those who have no evidence of neurological impairment

Exclusion Criteria

• Those who have decompensated liver cirrhosis
• Those who have a high MELD score (≥20)
• Those who have OHE during admission
• Those who have parients' refusal

• Minimum Eligible Age: 22 Years
• Maximum Eligible Age: 69 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Chuncheon Sacred Heart Hospital

OTHER

Sponsor Role: lead

Responsible Party

Ki Tae Suk

Proffesor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Ki Tae Suk

Role: PRINCIPAL_INVESTIGATOR

Hallym University Medical Center

Locations

Department of Internal Medicine, Hallym University Chuncheon Sacred Heart Hospital

Chuncheon, Gangwondo, South Korea

Countries

South Korea

Other Identifiers

YR

Identifier Type: OTHER

Identifier Source: secondary_id

COG

Identifier Type: -

Identifier Source: org_study_id